Sevgi Besisik
Overview
Explore the profile of Sevgi Besisik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atci T, Ozturk Sari S, Buyukbabani N, Besisik S, Baykal C
Int J Dermatol
. 2024 Mar;
63(10):1404-1413.
PMID: 38440839
Background: Tumors indicating the advanced stage of mycosis fungoides (MF) have a rich clinical spectrum. Although it is known that the prognosis of MF generally worsens following the development of...
2.
Dal M, Ulu B, Uzay A, Akay O, Besisik S, Yenerel M, et al.
Ann Hematol
. 2022 Nov;
102(1):133-140.
PMID: 36401621
Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL...
3.
Caliskan Y, Mirioglu S, Dirim A, Ozluk Y, Yegit O, Aksoy E, et al.
Ther Apher Dial
. 2022 Oct;
27(3):428-434.
PMID: 36201223
Introduction: We compared the outcomes associated with plasma exchange (PE), double filtration plasmapheresis (DFPP), or immunoadsorption (IA) in the treatment of late antibody mediated rejection (AMR). Methods: Sixty-nine kidney transplantation...
4.
Gelmez M, Oktelik F, Tahrali I, Yilmaz V, Kucuksezer U, Akdeniz N, et al.
Front Immunol
. 2022 Sep;
13:954391.
PMID: 36110850
Erroneous immune responses in COVID-19 could have detrimental effects, which makes investigation of immune network underlying COVID-19 pathogenesis a requisite. This study aimed to investigate COVID-19 related alterations within the...
5.
Safak S, Aksoy E, Dirim A, Demir E, Garayeva N, Oto O, et al.
Clin Kidney J
. 2021 Jun;
14(4):1287-1288.
PMID: 34094522
No abstract available.
6.
Anakli I, Ozcan P, Polat O, Orhun G, Alay G, Tuna V, et al.
Turk J Haematol
. 2021 Jan;
38(1):15-21.
PMID: 33486940
Objective: The defective interplay between coagulation and inflammation may be the leading cause of intravascular coagulation and organ dysfunction in coronavirus disease-19 (COVID-19) patients. Abnormal coagulation profiles were reported to...
7.
Sariman M, Abaci N, Ekmekci S, Cakiris A, Percin Pacal F, Ustek D, et al.
Balkan Med J
. 2018 Aug;
36(1):23-31.
PMID: 30079703
Background: Multiple myeloma is a plasma cell dyscrasia characterized by transformation of B cells into malignant cells. Although there are data regarding the molecular pathology of multiple myeloma, the molecular...
8.
Tekgunduz E, Demirkan F, Vural F, Goker H, Ozdogu H, Kiki I, et al.
Transfus Apher Sci
. 2017 Nov;
56(6):804-808.
PMID: 29153305
Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront...
9.
Atci T, Yazganoglu K, Yonal I, Polat Ekinci A, Kaplan S, Babuna G, et al.
J Dtsch Dermatol Ges
. 2017 Feb;
15(2):214-217.
PMID: 28214299
No abstract available.
10.
Atci T, Yazganoglu K, Yonal I, Polat Ekinci A, Kaplan S, Babuna G, et al.
J Dtsch Dermatol Ges
. 2017 Jan;
15(2):215-218.
PMID: 28084678
No abstract available.